Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I/Ib Open-Label Dose Escalation and Expansion of Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
Study Type: Treatment
Phase: I
NCTID: NCT04277637
Principal Investigator:
Marc Hoffmann
Phase II/III Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax U2-V Compared to Ublituximab and Umbralisib U2 in Subjects with Chronic Lymphocytic Leukemia CLL
Study Type: Treatment
Phase: II
NCTID: NCT03801525
Principal Investigator:
Marc Hoffmann
Risk-Based, Response-Adapted, Phase II Open-Label Trial of Nivolumab + Brentuximab Vedotin N + BV For Children, Adolescents, and Young Adults with Relapsed/Refractory R/R CD30 + Classic Hodgkin Lymphoma Chl After Failure of First-Line Therapy, Followed By Brentuximab + Bendamustine BV + B for Participants with a Suboptimal Response
Study Type: Treatment
Phase: II
NCTID: NCT02927769
Principal Investigator:
Kevin Ginn
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors DAWT and Relapsed Favorable Histology Wilms Tumors FHWT
Study Type: Treatment
Phase: II
NCTID: NCT04322318
Principal Investigator:
Keith August
A Phase II Study of Loxo-292 in Patients with Ret Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer LUNG-MAP Sub-Study
A Phase III, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression: SORAYA
A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Sexual Health Empowerment for Jail-Involved Women's Health Literacy and Prevention SHE-Women
Study Type: Screening
Phase: N/A
NCTID: NCT03984695
Principal Investigator:
Megha Ramaswamy
A phase I/II trial of Cabozantinib in combination with Durvalumab MEDI4736 with or without Tremelimumab in patients with advanced gastroesophageal cancer and other gastrointestinal GI malignancies CAMILLA
A Randomized Phase II study of Brentuximab Vedotin NSC 749710 and Crizotinib NSC 749005 in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma ALCL IND 117117
Study Type: Treatment
Phase: II
NCTID: NCT01979536
Principal Investigator: